Sunshine Biopharma Parent Company Awarded Research Grant of $940,000 to Advance Adva-27a Cancer Drug Candidate
July 16 2013 - 08:00AM
Marketwired
Sunshine Biopharma Inc. (OTCQB: SBFM) is pleased to announce that
its parent company, Advanomics Corporation, has been awarded a
research grant from the prestigious agencies Natural Sciences and
Engineering Research Council of Canada ("NSERC") and NanoQuebec to
advance the development of Adva-27a, the Company's flagship
oncology compound targeted for multidrug resistant cancers. The
grant, in the amount of $940,000, was awarded to Advanomics
Corporation in collaboration with Ecole Polytechnique.
In its letter of offer, NSERC states: "The [Advisory] Committee
was impressed by the calibre of the research team, the scientific
merit of the proposal, and the potential training
opportunities."
Adva-27a is Advanomics Corporation's and Sunshine Biopharma's
lead anticancer compound, a small molecule that has recently been
shown to be effective at killing multidrug resistant breast cancer
cells, small-cell lung cancer cells, uterine sarcoma cells and
pancreatic cancers cells (Published in ANTICANCER RESEARCH, Volume
32, Pages 4423-4432, October 2012). Adva-27a is currently in the
IND-Enabling stage of development. The original US patent covering
Adva-27a was issued on August 7, 2012 under US patent number
8,236,935.
"This is a big stamp of approval for Adva-27a," said Dr. Steve
N. Slilaty, CEO of Sunshine Biopharma. "Our clinical trials are
rapidly approaching and we could not be happier that such
distinguished and experienced agencies are impressed by our
compound. We are extremely grateful for the dedication and support
of NSERC, NanoQuebec and Ecole Polytechnique which dovetails with
our goal to develop new therapeutics for cancer."
About Advanomics Corporation Advanomics
Corporation is a privately held Canadian company (55% shareholder
of Sunshine Biopharma Inc.) focused on the research and development
of treatments for cancer and other human diseases. Advanomics is
conducting research and development in the areas of siRNA and
Carbon-Difluoride Chemistry to generate novel anticancer
compounds.
Safe Harbor Forward-Looking Statements To
the extent that statements in this press release are not strictly
historical, including statements as to revenue projections,
business strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial conditions, future
collaboration agreements, the success of the Company's development,
events conditioned on stockholder or other approval, or otherwise
as to future events, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made.
For Additional Information Contact: Camille Sebaaly CFO
Sunshine Biopharma Inc. Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com www.sunshinebiopharma.com